Results from Phase 1b/2a study of efzofitimod in pulmonary sarcoidosis patients demonstrate safety and dose dependent trends of improvement compared to placebo for key efficacy endpoints.
Read more at globenewswire.comProvided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.